WallStreetZenWallStreetZen

NASDAQ: BMRN
Biomarin Pharmaceutical Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Biomarin Pharmaceutical revenue was $2.85B for the trailing 12 months ending Dec 31, 2024, with 152.8% growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $747.3M, up 0.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BMRN annual revenue was $2.9B, with 18% growth year-over-year.

BMRN past revenue growth

How has BMRN's revenue growth performed historically?

Company
17.97%
Industry
437.31%
Market
20.27%
BMRN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BMRN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BMRN's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

BMRN revenue history

Current Revenue
$2.9B
Current Earnings
$426.9M
Current Profit Margin
15%

Be the first to know when BMRN announces revenue.

BMRN Revenue History By Year

BMRN Yearly RevenueBMRN RevenueBMRN ChangeBMRN Revenue Growth
2024-12-31$2.85B$434.69M+17.97%
2023-12-31$2.42B$323.19M+15.42%
2022-12-31$2.10B$249.76M+13.53%
2021-12-31$1.85B-$14.18M-0.76%
2020-12-31$1.86B$156.41M+9.18%
2019-12-31$1.70B$212.84M+14.27%
2018-12-31$1.49B$177.57M+13.52%
2017-12-31$1.31B$196.79M+17.62%
2016-12-31$1.12B$226.96M+25.50%
2015-12-31$889.90M$140.61M+18.77%
2014-12-31$749.28M$200.80M+36.61%
2013-12-31$548.49M$47.76M+9.54%
2012-12-31$500.72M$59.37M+13.45%
2011-12-31$441.36M$65.09M+17.30%
2010-12-31$376.27M$51.61M+15.90%
2009-12-31$324.66M$28.16M+9.50%
2008-12-31$296.49M$174.91M+143.86%
2007-12-31$121.58M$37.37M+44.38%
2006-12-31$84.21M$58.54M+228.06%
2005-12-31$25.67M$7.03M+37.70%
2004-12-31$18.64M$6.54M+54.06%
2003-12-31$12.10MN/AN/A
2002-12-31$0.00N/AN/A
2001-12-31$0.00-$9.71M-100.00%
2000-12-31$9.71M$4.41M+83.28%
1999-12-31$5.30M$4.11M+345.38%
1998-12-31$1.19M-$873.92k-42.34%
1997-12-31$2.06M$733.28k+55.11%
1996-12-31$1.33MN/AN/A

1 of 2

Biomarin Pharmaceutical Revenue FAQ

What was BMRN's revenue last quarter?

On Invalid Date, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q4 2024 revenue of $747.31 million up 15.65% year over year. In the same quarter last year, Biomarin Pharmaceutical's revenue was $646.21 million.

What was Biomarin Pharmaceutical's revenue in 2024?

Biomarin Pharmaceutical's annual revenue for the twelve months ending Dec 31, 2024 was $2.85 billion, a 17.97% increase year over year.

How much does Biomarin Pharmaceutical make in a day?

Based on Biomarin Pharmaceutical annual revenue for the past five years, BMRN makes an average of $6,068,991.78 per day.

What was Biomarin Pharmaceutical's annual revenue growth in the past year?

As of Q2 2025, Biomarin Pharmaceutical's revenue has grown 17.97% year over year. This is 419.34 percentage points lower than the US Biotechnology industry revenue growth rate of 437.31%. Biomarin Pharmaceutical's revenue in the past year totaled $2.85 billion.

How much does Biomarin Pharmaceutical make in a year?

Biomarin Pharmaceutical's revenue by year for the past five years is:
  • Biomarin Pharmaceutical's revenue for the twelve months ending Dec 31, 2024 was $2.85 billion, a 17.97% increase year over year.
  • Biomarin Pharmaceutical's annual revenue for Dec 31, 2023 was $2.42 billion, a 15.42% increase from 2022.
  • Biomarin Pharmaceutical's annual revenue for 2022 was $2.10 billion, a 13.53% increase from 2021.
  • Biomarin Pharmaceutical's annual revenue for 2021 was $1.85 billion, a 0.76% decrease from 2020.
  • Biomarin Pharmaceutical's annual revenue for 2020 was $1.86 billion, a 9.18% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.